Taconic Biosciences and TransCure bioServices: Humanized Research to Support Translational Decisions

On January 20, 2026, Taconic Biosciences announced the acquisition of TransCure bioServices, a leading provider of contract research services utilizing humanized mouse models. This acquisition brings together Taconic’s globally produced genetically engineered and humanized mouse models with TransCure bioServices’s translational pharmacology and in vivo preclinical expertise, creating a comprehensive, end-to-end humanized mouse translational research platform.

Customers gain access to a more integrated and streamlined research experience. The combined platform enables seamless progression from model generation and humanization through cohort development and advanced in vivo studies, reducing multi-vendor complexity, improving data continuity, and accelerating time-to-decision across discovery and translational programs.

No immediate changes are expected. TransCure bioServices will continue to operate under its established brand and operational structure. Existing projects, contracts, and scientific contacts will remain in place, with the added benefit of expanded capabilities and global infrastructure through Taconic.

Customers now have access to:

• Study-ready humanized immune system (HIS) mice with verified immune function
• Characterized CDX and PDX models in HIS mice
• Humanized liver mouse models for pharmacological studies
• Mechanism-of-action–aligned study designs
• Advanced immune profiling, flow cytometry, imaging, and histopathology
• Standardized workflows that improve reproducibility
• Accelerated timelines from model design to final data readout

The integrated platform supports key therapeutic areas including oncology, liver, immunology, infectious disease, inflammation, and metabolic disease. It is specifically designed for complex, mechanism-driven modalities such as bispecific antibodies, antibody-drug conjugates (ADCs), CAR-T and CAR-NK therapies, innate immune agonists, tumor microenvironment modulators, and other next-generation therapeutics.

By aligning model selection, humanization strategy, and study design within a single scientific framework, the platform improves biological relevance to human disease. The integration of validated models with disease-specific translational pharmacology and mechanistic readouts reduces variability and enhances confidence in translational and IND-enabling decisions.

HIS models are delivered as study-ready cohorts with verified immune reconstitution. Immune profiling and quality control assessments—including flow cytometry and functional validation—confirm engraftment efficiency, lineage distribution, and immune competence prior to study initiation, supporting consistency and reproducibility.

Yes. Study designs are tailored to the therapeutic mechanism of action, disease biology, and model characteristics. Customization options include cohort design, dosing strategies, endpoint selection, biomarker panels, and depth of immune and tissue profiling to ensure alignment with program-specific scientific objectives.

Standardized workflows across model generation, humanization, cohort development, and in vivo execution are applied within a unified quality system. A single accountable scientific partner and defined chain of custody reduce variability associated with multi-vendor handoffs and improve comparability across studies and programs.

Integrated access to validated models, mechanism-aligned study designs, and advanced in vivo pharmacology shortens timelines from study initiation to actionable data. This enables earlier, higher-quality insights that support faster progression toward IND-critical milestones while mitigating translational risk.

Both Taconic and TransCure bioServices are AAALACi-accredited and maintain rigorous standards for scientific quality, animal welfare, and operational transparency across U.S. and European facilities. The integrated platform supports responsible innovation by improving model fidelity, reducing unnecessary repetition, and incorporating New Approach Methodologies (NAMs) where appropriate.

Customers should continue to work with their existing scientific and commercial contacts. Additional inquiries may be directed to Taconic through the contact information provided on the Taconic website.